天目药业前三季度扭亏为盈，黄山技改项目稳步推进

Group 1 - The core viewpoint of the article highlights the significant improvement in Tianmu Pharmaceutical's performance, with a revenue of 159 million yuan for the first three quarters of 2025, representing a year-on-year increase of 27.48%, and a net profit of 14.21 million yuan, marking a turnaround from losses [1] - As of February 11, 2026, the company's stock price is reported at 20.59 yuan per share, with a total market capitalization of approximately 2.507 billion yuan, reflecting a cumulative increase of 18.95% year-to-date [1] Group 2 - The company is making steady progress on its Huangshan technical transformation project, with the main structure of phase one already completed and expected to commence production by the end of 2026, which will enhance the capacity for traditional Chinese medicine extraction and formulation [2] - The company's product resumption plans, such as the Pearl Eye Drops, and channel expansion efforts, including the establishment of a national marketing system, are ongoing [2]